Putnam FL Investment Management Co. bought a new stake in shares of Thermo Fisher Scientific Inc (NYSE:TMO) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 29,836 shares of the medical research company’s stock, valued at approximately $5,645,000.
Several other large investors also recently modified their holdings of TMO. Proficio Capital Partners LLC boosted its stake in shares of Thermo Fisher Scientific by 71.5% during the 1st quarter. Proficio Capital Partners LLC now owns 607 shares of the medical research company’s stock valued at $105,000 after buying an additional 253 shares during the period. Chicago Partners Investment Group LLC acquired a new stake in shares of Thermo Fisher Scientific during the 2nd quarter valued at $108,000. Shine Investment Advisory Services Inc. acquired a new stake in shares of Thermo Fisher Scientific during the 2nd quarter valued at $113,000. Ropes Wealth Advisors LLC boosted its stake in shares of Thermo Fisher Scientific by 15.8% during the 2nd quarter. Ropes Wealth Advisors LLC now owns 710 shares of the medical research company’s stock valued at $124,000 after buying an additional 97 shares during the period. Finally, Atlantic Trust LLC acquired a new stake in shares of Thermo Fisher Scientific during the 2nd quarter valued at $138,000. 86.16% of the stock is owned by institutional investors.
A number of equities research analysts have issued reports on the stock. Jefferies Group reissued a “hold” rating and set a $195.00 target price on shares of Thermo Fisher Scientific in a research note on Thursday, September 28th. Zacks Investment Research raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $208.00 price objective for the company in a research note on Thursday, September 7th. Leerink Swann reaffirmed an “outperform” rating and issued a $200.00 price objective (down previously from $216.00) on shares of Thermo Fisher Scientific in a research note on Monday. Argus reaffirmed a “buy” rating on shares of Thermo Fisher Scientific in a research note on Tuesday, August 22nd. They noted that the move was a valuation call. Finally, Morgan Stanley reaffirmed an “overweight” rating and issued a $220.00 price objective on shares of Thermo Fisher Scientific in a research note on Wednesday, September 6th. One research analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $205.21.
Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, October 25th. The medical research company reported $2.31 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.24 by $0.07. The firm had revenue of $5.12 billion during the quarter, compared to analyst estimates of $5.03 billion. Thermo Fisher Scientific had a net margin of 11.73% and a return on equity of 15.94%. The business’s revenue was up 13.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.03 EPS. sell-side analysts anticipate that Thermo Fisher Scientific Inc will post 9.36 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Monday, January 15th. Shareholders of record on Friday, December 15th will be given a dividend of $0.15 per share. This represents a $0.60 dividend on an annualized basis and a yield of 0.33%. The ex-dividend date of this dividend is Thursday, December 14th. Thermo Fisher Scientific’s dividend payout ratio is 10.19%.
In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 50,000 shares of the business’s stock in a transaction on Wednesday, November 15th. The shares were sold at an average price of $188.39, for a total transaction of $9,419,500.00. Following the completion of the transaction, the chief executive officer now owns 252,577 shares of the company’s stock, valued at approximately $47,582,981.03. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.49% of the stock is owned by insiders.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
What are top analysts saying about Thermo Fisher Scientific Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Thermo Fisher Scientific Inc and related companies.